FDA: PPIs and Clostridium Difficile

Published Online: Friday, July 20, 2012
Follow Pharmacy_Times:
In this podcast, Steve Jackson, a pharmacist in the FDA’s division of drug information, warns that use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea.
 
To listen to the podcast, click here.
Related Articles
Roche’s new tests to detect Clostridium difficile and genital herpes infection have been cleared by the FDA.
Barrett’s esophagus (BE) is a serious gastrointestinal condition in which acid reflux predisposes the esophagus to increased cell proliferation and decreased apoptosis.
The FDA today approved eluxadoline and rifaximin to treat irritable bowel syndrome with diarrhea.
Clostridium difficile-associated diarrhea (CDAD) is an increasingly common cause of inpatient mortality, and recurrent CDAD remains clinically challenging.
Latest Issues
$auto_registration$